Introduction
Since its introduction in 1977[1J,percutaneous transluminal coronary angioplasty has proved to be a successful method in the treatment of coronary artery disease. However, restenosis, which constitutes the major problem following successful angioplasty, occurs in 30-40'% of patients (range 20--70%) within 3-6 months[2-12J, despite extensive efforts to reduce its incidence [13] [14] [15] [16] . These include the administration. of drugs such as warfarin [17.18] , calcium channel-blocking ;gents[l9-21], aspirin[22J, ticlopidine[23J, prostacyclin [24] , thromboxane Arreceptor blocker[25J, colchicine [26] , corticosteroids [27] and lipid-lowering regimens [3.4,6,7,28-32J, Restenosis may be viewed as a multifactorial response of the vascular tissue to balloon injury. Several interactive processes are involved: mechanical factors (medial dissection and intimal fiap formation, elastic recoil and 1 ';e'~'>";;;".;;;""~'
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local application of high concentrations of magnesium and repeated intravenous infusions of magnesium solutions in animals suppressed thrombus formation at intimal lesions [45.53] . Thus, the antivasospastic[54j and antithrombotic [55] [56] [57] [58] effects of magnesium, together with reduction of smooth muscle contraction at the angiop]asty site, might minimize ongoing endothelial trauma and platelet deposition in the early hours after the procedure and have a beneficial effect on restenosis.
The current study was designed to evaluate the effectiveness of magnesium in decreasing the rate of restenosis in patients undergoing successful percutaneous transluminal coronary angioplasty.
]'ylethods STlJDY POPULATION AND RANDOMIZATION
The study was designed as an open-labelled randomized and controlled trial. The patients were randomized in a 2: 1 fashion to maximize the number of patients treated with intravenous magnesium and to encourage patient enrolment while preserving the statistical advantage of a randomized design. One hundred and fortyeight consecutive patients with either stable or unstable anginal syndrome, who underwent successful coronary angioplasty without complications du.ring the following 24 h (death, acute myocardial infarction, coronary artery bypass grafting, repeat angioplasty or recurrence of angina), were included. After completing the entry angiogram, 98 patients were randomized to receive magnesium intravenously (groups MI and M2), of whom 49 continued oral supplements of magnesium (group M2). The other 50 patients received no magnesium and served as the control group (group C).
Exclusion criteria included: age < 18 or > 80 years, unreliable or noncooperative patient, active drug or alcohol abuse, inaccessibility for follow-up, antimalignancy or immunosuppressant therapy, a history of or an existing clinical condition which may lead to hypomagnesaemia (ileal resection, etc.), myocardial infarction within the 5 days preceding the procedure, uncontrolled hypertension or diabetes, severe allergy to contrast media, contraindication to aspirin (active peptic ulcer, allergy, etc.), evidence of chronic renal disease or failure (urolithiasis or serum creatinine >2.0 mg%), systolic arterial blood pressure <90 mmHg, atrioventricular or sinoatrial block of second or third degree, a totally occluded vessel, previous angioplasty in the artery to be dilated or any coronary bypass surgery.
STUDY PROTOCOL
The experimental protocol was approved by the Human Subjects Review Committee of the Sourasky Medical Center and all patients gave written informed consent.
Angioplasty procedures and quantitative analysis
All patients received sublingual nitroglycerin (0,6 mg) before angiography.(at baseline and at follow-up an- 
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Effect of magnesium on restenosis after PT.CA 1165 giography) to avoid coronary spasm. Intravenous morphine was administered as required for chest pain. After placement of a vascular sheath, 5000 U heparin was administered intravenously. Once it was determined that a patient was suitable for angioplasty, an additional 10 000 U intravenous heparin was given. Intracoronary nitroglycerin (0-1 mg) was administered during coronary angioplasty to aUpatients in all groups before performing the angiogram, which was to be analysed foIJowing the procedure. Coronary angioplasty was performed using standard available balloon catheters sized to the normal lumen diameter of the artery to be dilated. Inflation duration and pressure was left to the discretion of the angioplasty operator. Upon completion of the procedure, la min were allowed to pass before resuming angiograms of the dilated vessel. The performance of an angiogram of the contralateral vessel for the purpose of assessing the presence or absence of collaterals concluded the session. A final angiogram was carried out 6 months later unless the patient's clinical condition necessitated earlier intervention. If no restenosis was present and the foIJow-up time was <2 months, the patient was requested to undergo a further coronary angiogram at 6 months.
Qualitative analysis of coronary morphology was obtained by consensus at a blinded review of the angiograms by a panel of three experienced cardiologists. Angiographic projections and cine frames were selected to visualize vessel segments as nearly perpendicular as possible to the imaging axis to minimize shortening, and an end-diastolic frame was selected for analysis, Quantitative analysis of the lesions before and after angioplasty and at follow-up was performed in identical angiographic projections by means of manual edge detection and computer-assisted calculations previously described elsewhere [59] . The catheter was used as an object of known dimensions providing calibration for measurements of coronary vessels. The actual outside diameter of the catheter was manually entered into the computer for calculation of the magnification factor. The diame'ters for the 7F and 8F Judkins catheters used were 2.25 mm and 2.45 mm, respectively. Successful angioplasty was defined as at least 20% reduction in luminal stenosis diameter of the dilated segment and <50% diameter stenosis immediately after angioplasty. Restenosis was defined as a narrowing> 50% at the site of previous dilation measured from the same angiographic view.
Drug regimen
In groups MI and M2, a bolus of 1 g (4 mmol) magnesium sulphate (MgSO4)was infused intravenously over a 10min period prior to the initiation of angioplasty, followed by an infusion of 0.04 mmol . min -1 throughout the procedure and for 18-20 h thereafter. In group M2, the first oral dose of magnesium hydroxide [Mg(OH2)]300 mg b.i.d. was initiated 3 h before discontinuation of the intravenous drip. A continuous heparin infusion (begun during angioplasty) was administered for 12 to 18 h and stopped routinely 4 h before thẽ 
Patient managementalld folloll'-IIP
After coronary angioplasty, patients were transferred to the cardiology ward where they were monitored. with vital signs being frequently taken for at least 24 h. When a haematoma developed at the location of the intravascular sheath, heparin was discontinued earlier. A l2-lead electrocardiogram was obtained immediately in the event of any chest discomfort and, if ischaemia was suspected, creatine kinase levels were measured and cardiac catheterization was performed again. Patients were routinely discharged I to 2 days after coronary angioplasty. A l2-lead electrocardiogram was recorded upon discharge. Patients were seen at the outpatient clinic at 1, 2, 3, and 6 months for a check-up including laboratory tests, l2-lead electrocardiogram and a tablet count and a new supply of trial medication for those in group M2. Left ventricular function was assessed by two radionuclide studies which the patients underwent 24-72 h following angioplasty and immediately before the follow-up angiogram.
A modified Bruce protocol was performed at 1 week and at 3 and 6 months following angioplasty. Twelvelead electrocardiographic recordings and blood pressure measurements (cuff) were obtained at rest and at the end of each stage during exercise, at the point of 1 mm ST segment depression, at peak exercise and at 3 and 6 min into the recovery period. A positive exercise test indicative of myocardial ischaemia was defined as horizontal or downsloping ST segment depression~1 mm (0'1 mV) measured 60 ms after the J point or ST segment elevation in Q wave leads in which there was enough preservation of R waves. The exercise test was stopped in the event of chest pain of moderate severity, or the patient's inability to exercise further. For purposes of final analysis, only those who had at least two comparable stress tests at follow-up were included.
Laboratory tests
These were obtained at baseline and at follow-up clinic visits and included determination and measurement of: full blood chemistry (Beckman Synchron CX3, Beckman Instruments Inc, Brea, CA, USA.) including magnesium levels (determined by atomic absorption spectrophotometry Perkin-Elmer 3100, Norwalk, Connecticut, D.S.A.), full blood count, prothrombin time and partial thromboplastin activity, serum lipidophoresis [determination of total cholesterol, triglycerides and high-(HDL) and low-(LDL) density lipoprotein using a Bohringer-Hitachi 737 analyser, Mannheim, Germany] and urinalysis. In addition, a 24 h collection of urine was obtained each time for the measurement of magnesium, calcium, phosphorous, sodium, potassium and creatinine.
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Drug compliance
Patients \vere questioned about capsule intake at the foIJow-up visits and requested to collect the empty medication containers and bring them for counting.
Compliance was also assessedby subsequent analysis of the fractional excretion of magnesium, calculated as follows: (urine magnesium/plasma magnesium) x (plasma creatinine/urine creatinine) x 100. In addition. blood samples were drawn for magnesium levels immediately before discontinuation of magnesium drip.
DATA REVIEW
The followIng variables were analysed. Clinical: age, gender, current smoking habits, diabetes meIlitus, hypertension, hyperlipidaemia, duration of angina, type of angina or recent myocardial infarction, location of infarction, recent (up to 30 days) use of an intravenous thrombolytic agent, and clinical status during follow-up and upon completion of the study. Angiographic: the pre-and post-angioplasty as well as follow-up features of the dilated artery included the following variables assessed at an end-diastolic frame: dilated artery, proximal mid-or distal stenosis location, single-, double-or triple-vessel disease using the 50% diameter stenosis definition, length of the stenosis, location of the stenosis at a bend >45", branch point location, the preangioplasty presence of contrast staining or a filling defect suggestive of thrombus and collateral circulation to the dilated artery.
REPRODUCIBILITY AND INTEROBSER VER VARIABILITY
The stenosis morphology and quantitation was assessed independently at random by three experienced cardiologists. The reproducibility of these measurements was assessed by complete reanalysis of the angiograms of 50 of the lesions by the sameteam and a goodlevelof agreement was obtained (Table 1) .
STATISTICAL ANALYSIS
All results of continuous variables are expressed as mean:!: 1 standard deviation. Differences between continuous variables were compared using the StUdent's t-test for two groups and multiple analysis of variance for the repeated measurements. Differences between discrete variables were compared by using univariate chi-squared analysis. A value of P<0'05 was considered significant.
Results

PATIENT POPULATION
Starting in May 1990 and ending in December 1992, 160 patients were randomized with the 2:1 randomization scheme to receive magnesium. Within this group, 105were randomized for magnesium and 55 for controL Of these, two patients in each group refused to continue the study shortly after they had given their consent.
,--~c_::c_,,-,,__.c.:,:"L;=""'.iJ",0"'""':':'_'-;:""'::"-_:.-:-"::" ..f!' ,... "... CSA=cross-sectional area; SEE=standard error of estimate. Coronary angioplasty failed in two of the control group and in three of the magnesium group. One patient in the control group underwent urgent coronary bypass (due to coronary dissection) and magnesium infusion was stopped prematurely (after 3 and 5 h from initiation) by mistake in two patients of the magnesium group. Thus, of the remaining 148 patients, 98 patients (66%) were randomized to intravenous magnesium and 50 patients (34%) served as control. Forty-nine' patients who received intravenous magnesium continued on a regimen of oral magnesium capsules for 6 months until the final angiogram. A total of 139patients (94%) completed the study with a follow-up angiogram while nine patients (most of them having had a complete clinical follow-up) refused the final angiogram (they included four patients in the control group, four in group Ml and one in group Ml). These nine patients were excluded from the final analysis. The demographic, selected laboratory and angiographic characteristics were similar in the three patient groups and these data are presented in Tables 2  and 3 .
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EFFECTS OF INTRA VENOUS MAGNESIUM ADMINISTRATION
Intravenous magnesium was well tolerated and no serious adverse effects were observed during administra- t, ".
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".- tion. Systolic blood pressure dropped in two patients shortly after initiation of intravenous magnesium. The magnesium infusion was discontinued, fluids were administered and the magnesium infusion was later resumed. The clinical course of these two patients was uneventful thereafter. Flushing was observed in 8/98 (8%) patients, but only two complained about it. In the magnesium groups, serum magnesium levels increased significantly after completion of magnesium infusion (dosage 46-52 mmol over 18-20 h) compared with baseline (from 1.98:1:0,47 to 3,13 :I:O' 55 mg%, P= 0,001).
In the magnesium-treated groups, coronary angioplasty resulted in an increase from 0,9:1:0,6 to 4.5:1:2.1 mm2 in the cross-sectional area at the site of dilatation and a reduction in percent diameter stenosis from 66:1:9 to 24:1:12%. The corresponding improvement in cross-sectional area in the control group was from 1.0:1:0,8 to 3,9:1:1.8mm2 and from 65:1:9% to 24:1: 12% in percent diameter stenosis. The increase in the cross-sectional area was more pronounced in the magnesium-treated groups (3'55:1:2.01 mm2) than in the control group (2'90:1:1.63 mm2, P=0'031). Thevasodilatory properties were also evident in the reference segment where intravenous magnesium induced an increase of 0. in the control group (Fig. 1) . ,Magnesium effects were not related to the dilated artery, shape or location of stenosis or to any of the clinical or laboratory parameters examined. It should be noted that in the entire study population, the mean cross-sectional area of the dilated segments which did not restenose (n= 115) after angioplasty, was significantlylarger than those segments which restenosed (4'5:1:2.1 mm2 vs 3.6:1:1.7mm2, P=O'OI). This was not related to the degree of diameter stenosis after angioplasty which was identical for patients who either did or did not restenose (24:1:12%).
EFFECTS OF ORAL MAGNESIUM ADMINISTRATION
Oral magnesium was well tolerated with only few side effects. Table 4 of the dilated segment was demonstrated, and these patients were referred for emergency coronary bypass surgery-Four more control patients and one groupM1 patient were referred for surgery during follow-up, in comparison to none of the patients who received oral magnesIUm.
. The rate of restenosis (defined as > 50% reduction in the luminal diameter at site of angioplasty) tended to be lower in groups M1 and M2 (14/53:26% and 14/57:25%,-respectively) compared with group C (20/53:38%). This difference was not statistically.significanL However, if both magnesium-treated groups in combination are compared to the control group, a .trend toward a lower occurrence rate of restenosis is noticed for those who 
GENERAL EFFECTS OF MAGNESIUM AND PATIENT
COMPLIANCE
Oral administration of magnesium was well tolerated and no adverse gastrointestinal effects were reported throughout follow-up. Interestingly, more patients in group M2 reported improved 'well-bei:qg'than those not receiving oral magnesium.
At the end of the study, no difference was observed in serum magnesium levels in group M2 (2' There is continued improvement in both initial success rates of coronary angioplasty and in the introduction of new devices to complement balloon angioplasty, in addition to a reduced initial complication rate. Nevertheless, a physiologically significant stenosis recurs within 6 months at the site of angioplasty in approximately 30-40% of patients. This rate of restenosis has remained constant despite multiple pharmacological approaches directed towards the prevention of vascular responses which underlie restenosis [60] [61] [62] . Warfarin, for example, was initiated to affect the haemostatic mechanism, aspirin to affect thrombocytes and calcium channel blockers to modify mechanical factors (vasospasm) and cellular proliferation. Ma~esium has unique characteristics: it is a vasodilator [38] [39] [40] and has a profound effect on haemostasis [45] .
In vitro studies have shown that magnesium deficiency constricts isolated dog [40] and human [63] coronary arteries and that magnesium repletion dilates them. Reduction of Mg+2 in smooth muscle preparations increases vascular tone and potentiates the pressor action of angiotensin n [64] .In addition, it was shown that increased concentration of extracellular Mg+2 reduced platelet aggregation and the release reaction [65] .Some authors have suggested that magnesium deficiencymight adversely influence the healing and reendothelialization of vascular injuries [66] . This could contribute to thrombosis [45] and, therefore, to excessivesubintimal proliferation of smooth muscle cells [48,67J , changes that could lead to the development of atheromatous plaques. Thus, the antithrombotic and antivasospastic effects of magnesium were expected to improve the problem of restenosis.
DOES MAGNESIUM PROTECT AGAINST RESTENOSIS?
In this study, the overall segmental restenosis rate was 29'4% (48/163 segments). Patients treated with intravenous magnesium tended to have a lower rate of restenosis (28/110 segments) compared to the control group (20/53 segments, P=Q.lO. This distinction in our study was based on a definition of restenosis as the stenosis being-greater than~O%'of the diameter. As previously shown in animals, this degree of stenosis is functionally and physiologically relevant and causes blunting of coronary flow reserve [68, 69] .
Both coronary spasm and elastic recoil, which occurs immediately after angioplasty at the angioplasty site[7O], have been associated with recurrent stenosis, since the early days of coronary angioplasty [35] .It was shown [7] ] that 4 h after coronary angioplasty, transient spontaneous vasoconstriction of the dilated and distal segments occurs, and to a levelso intense that the cold pressor test does not cause any further constriction. These abnormalities resolve within 8 days of coronary angioplasty.It was demonstrated also that ergonovine-induced coronary artery vasoreactivity at the angioplasty site was associated with more than twic;ethe recurrent stenosis rate [72] .Stretching of the coronary artery and elastic recoil of the dilated segments as a mechanism involved in angioplasty were recently demonstrated by intravascular ultrasound [73] . Despite this firm correlation, several randornized trials of calcium antagonists given after coronary angioplasty have failed to demonstrate a decrease in recurrent stenosis, either because these drugs are not powerful enough to change local 'coronary tone or because the spasm is merely a marker for a lesion likely to recur, i.e. spasm is associated with recurrence but does not cause it.
We have shown that magnesium exerted a marked additive coronary vasodilatory' effect (Fig. I) on the vesselsalready dilated by pre-angioplasty administration of nitrates. This response was noticed proximally and distally to the angiographically narrowed segments but was more pronounced at the angioplasty site. Thus, the injured dilated segment responds to the vasoreactive stimuli of magnesium in a profound manner. Given the significantly greater luminal diameter achieved postangioplasty in the magnesium groups, one could suppose that a more aggressive approach was taken in this treatment arm, although as is obvious from Table 3 , no differencein the technical approach was exerted between the groups. It is possible that the addition of a fourth arm to the study in which patients receive magnesium after dilatation to demonstrate the net vasodilator effect of magnesium perhaps would be optimal. Nevertheless, prevention of elastic recoil and the increased crosssectional area of the dilated segments may be the underlying mechanism for the tendency towards a lower restenosis rate in the magnesium-treated patients (25%) compared to controls (38%).
Magnesium taken orally did not result in any additive beneficial effectthroughout follow-up. Presumably, only the relatively high plasma levels attained with intravenous administration .are of value. These blood levels ' could not be attained during a 6-month period of oral treatment. This conclusion is corroborated by the small fraction absorbed and rapid clearance of the intravenous magnesium after cessation of infusion.
In this study, the changes observed in the dilated vessels during the acute and the long-term phase of magnesium administration did not correlate statistically, Although the rate of restenosis was 34% lower for the : magnesium-treated group comparedwith control (25% vs 38%), it was not statistically significant. This beneficial trend of magnesium to prevent acute recoil and late (within 6 months) restenosis is encouraging. Moreover, the inverse relationship we found between the tendency to restenosis in the whole study population and the size of the cross-sectional area achieved after angioplasty further emphasize the importance of reaching a maximally wide lumen of the vessel, in which the coronary vasodilatatory properties of magnesium may play an important role.
HO!vIEOSTASIS OF MAGNESIUM
Over the past decade, several reviews have focused on the relevance of magnesium in cardiac disease [49.67,75] . Magnesium, the fourth most abundant metal in living organisms and the second most prevalent intracellular cation, is distributed in three major compartments in the body: 65% in the mineral phase of the skeleton, 34% in the intracellular space, and only 1% in the extracellular fluid [76] ., ,
Magnesium concentration in various organs [77] [78] [79] does not correlate with serum magnesium level, and normal serum magnesium levels may exist in the presence of low tissue levels [38, 80, 8] ].
The recommended daily allowance of magnesium for a healthy adult is 5 mg . kg -] [67] . Urinary excretion is approximately 3 to 5% of filtered magnesium. With a rise in magnesium loading, the fraction of filtered magnesium excretion increases, as was also demonstrated in our study, during oral supplementation. On the other hand, a decreased concentration of serum magnesium, which occurs when a low-magnesium diet is ingested for a few days, leads to the near disappearance of magnesium from the urine.
Dietary surveys have shown that not even the modest, officially recommended magnesium intakes are met by most Americans and Canadians [82] .This causes cons;ern '---'0':""""-Effect of magnesium on restenos;s after PTCA 1171 malities noted. Upon cessation of intravenous administration, no rebound tachycardia, hypertension or chest discomfort were observed. No excessive bleeding through venous or arterial access sites was observed during infusion or at the time of intravascular sheath removal. However, although one of the presumed effects of magnesium is to decrease platelet aggregation, with this being a clinico-angiographic study, no platelet function or other coagulation test was perfonned (except for thrombin time and partial thromboplastin time, the results of which were normal for the whole patient population throughout the study).
CLINICAL IMPLICATION AND CONCLUSIONS
Intravenous administration of magnesium in patients undergoing coronary angioplasty is feasible and safe when applied to patients with systolic blood pressure >90 mmHg. Adverse effectsare seldom encountered and can easily be treated by the administration of fluids and temporary cessation of magnesium infusion. The rationale for the use of intravenous magnesium as adjuvant treatment during percutaneous coronary angioplasty seems to be promising. Oral administration of 600 mg magnesium per day does not have an additive effect on restenosis, but may result in an improved clinical course. Large-scale studies with a higher dose of magnesium applied during angioplasty and for a longer period thereafter seems warranted. 
